Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 25 (3) , 180-184
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Late-Onset Retinal Findings and Complications in Untreated Retinopathy of PrematurityOphthalmology Retina, 2019
- FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITYRetina, 2019
- Late ROP Reactivation and Retinal Detachment in a TeenagerOphthalmic Surgery, Lasers and Imaging Retina, 2018
- Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic FindingsOphthalmology, 2018
- Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)BMC Ophthalmology, 2018
- Reactivation of Retinopathy of Prematurity Three Years After Treatment With BevacizumabOphthalmic Surgery, Lasers and Imaging Retina, 2017
- Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal BevacizumabOphthalmic Surgery, Lasers and Imaging Retina, 2016
- Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser TreatmentJAMA Ophthalmology, 2014
- Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of PrematurityOphthalmology, 2014
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011